Skip to content

Effects of Vitamin D Supplementation on SOD,IL-6 and Insulin Resistance in Type 2 Diabetes Mellitus (DM)

THE EFFECT OF VITAMIN D SUPPLEMENTATION ON IMPROVING PANCREAS BETA CELL FUNCTION IN TYPE 2 DIABETES MELLITUS: STUDY OF SOD,IL-6,PDX-1 EXPRESSION, and INSULIN RESISTANCE

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05596383
Acronym
DM
Enrollment
112
Registered
2022-10-27
Start date
2022-02-12
Completion date
2023-06-23
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes Mellitus

Brief summary

The aim of this intervention clinical study are: evaluation the effect of vitamin D supplementation on anti-oxidant status, inflammation, insulin resistance in patients type 2 diabetes mellitus. The research question is how the effect of vitamin D supplementation for 3 and 6 months on anti-oxidant status, inflammation and insulin resistance in patients type 2 diabetes mellitus. The main tasks participants will be asked to do: * interviews, filling the questionnaires, and giving informed consent after receiving an explanation by the researcher about the purpose of the research * taking blood for screening examination which includes examination of Serum Glutamic Pyruvic Transaminase (SGPT), albumin, creatinine and blood Ca. * participant who meet the inclusion and exclusion criteria, performed a physical examination (height and weight) and blood collection for examination 25(OH)D. * Subjects/participant with vitamin D deficiency and insufficiency will be included in randomization, two groups: the group that received vitamin D3 5,000 IU and the group that received a placebo. Vitamin D 5000 IU and placebo taken daily for 6 months. * Observations for 3 months and 6 months from the first time supplementation was given. Treatments they'll be given: * During the study, the subject's clinical condition will be monitored. * Subject observations are monitored by telephone or google form to subject or their families

Detailed description

Participant register: Patients type 2 DM aged \> 18 years who went to the Community Health Centers Mampang were interviewed, filled out questionnaires, and gave informed consent.Interview by interviewers with at least high school education after being given training first by researchers. The data is entered in a computer excel table by the researcher. Accuracy, completeness of registration data using the screening form. Data that contains detailed descriptions of each variable used by the registry: * Gender: differences in the nature, form, and biological function of men and women that determine differences in reproduction, by interview using a questionnaire and identity card. * Duration DM: time from the first time being diagnosed DM until the start of the study, expressed in months * Subject's age: calculated from the time the study began with the date of birth listed on the identity card. Standard Operating Procedures to address registry operations and analysis activities: * patient recruitment : Patients type 2 DM aged \> 18 years who went to the Community Health Centers Mampang were interviewed. * data collection: using screening form * data management : using table excel computer * data analysis : using Statistical Package for the Social Sciences (SPSS) versi 23 * report for adverse event: using form adverse event Sample size assessment : formula for hypothesis testing the mean difference of two groups Plan for missing data : back up data Statistical analysis plan to address the primary and secondary objectives: normality test (kolmogorov Smirnov), test statistic (T independent test or Mann Whitney test, Anova test)

Interventions

DIETARY_SUPPLEMENTVitamin D 5000 IU

Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet

DIETARY_SUPPLEMENTPlacebo

Placebo

Sponsors

Trisakti University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

The study was divided into two groups, the intervention group and the control group. The intervention group received vitamin D 5000 IU/day for 6 months and the control group received a placebo (contains microcrystalline, calcium carbonate, sodium starch) for 6 months

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* male and female, aged \> 18 years * period of DM ≤ 3 years * using a single anti-diabetic drug (monotherapy) * HbA1c \> 6,5%

Exclusion criteria

* receive insulin therapy * kidney disease, liver disease * pregnant and lactating women * allergy history * hypercalcemia history * consumption of vitamin D in the last 3 months

Design outcomes

Primary

MeasureTime frameDescription
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)Change from Baseline at 3 and 6 monthsHOMA-IR : formula (fasting insulin (μIU/mL) x fasting blood glucose (mg/dL)/405
level of Superoxide Dismutase (SOD)Change from Baseline at 3 and 6 monthsSOD
Interleukin-6 (IL-6)Change from Baseline at 3 and 6 monthsIL-6 in monocyte: % (method immunoflowcytometry);
pancreatic and duodenal homeobox 1(PDX-1) expressionChange from Baseline at 3 and 6 monthsPDX-1 expression : ct (method polymerase chain reaction /PCR);

Secondary

MeasureTime frameDescription
vitamin D levelChange from Baseline at 3 and 6 monthsVitamin D: ng/mL;
(hemoglobin glycate) HbA1CChange from Baseline at 3 and 6 monthsHbA1c: % ;
fasting blood glucoseChange from Baseline at 3 and 6 monthsFasting blood glucose: mg/dL ;
fasting insulinChange from Baseline at 3 and 6 monthsFasting insulin: μIU/mL

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026